Linear Growth as a Function of Age at Onset of Puberty and Sex Steroid Dosage: Therapeutic Implications*

JEAN-PIERRE BOURGUIGNON*

Department of Pediatrics and Radioimmunoassay Laboratory, University of Liège, CHU Sart-Tilman, B-4000 Liège, Belgium

I. Introduction

Puberty plays a dual role in growth: height velocity is markedly accelerated while the rate of skeletal maturation is also increased with resultant fusion of epiphyseal cartilages. Thus, puberty can be considered as a growth-promoting event as well as the final height-limiting process. This concept is illustrated by early exposure to sex steroids such as occurs in central precocious puberty or congenital adrenal hyperplasia. These conditions accelerate growth but result in short adult height (1-6).

The basic question addressed in this paper is how hormonal changes at puberty and the age of their occurrence influence growth rate and adult height. This query has practical implications including timing and dosage of sex steroid replacement therapy in hypopituitary patients and the use of GnRH agonist therapy in patients with precocious puberty or short stature. These issues may have profound social import since numerous (mostly uncharted) psychological aspects of adolescence may be related to stature and the timing of sexual development.

The following sections will review 1) the hormonal constituents of the pubertal spurt, 2) the auxological parameters important for evaluating growth at puberty and for predicting its importance for final height, 3) the role of sex steroid dosage, 4) the role of age at onset of puberty and, 5) some therapeutic implications.

II. The Hormonal Constituents of the Pubertal Growth Spurt

Several hormonal factors may interact to determine the pubertal growth spurt: GH, insulin-like growth factor I (IGF-I), and sex steroids (androgens, estrogens) of gonadal and adrenal origins. The permissive role of thyroid hormones and the interactions of insulin and nutrition will not be discussed. The aim of this section is to examine the respective roles of GH, IGF-I, and sex steroids in eliciting the pubertal growth spurt.

A. Gonadal sex steroids

Growth-promoting effects independent of GH. In both sexes, the role of gonadal steroids is obvious from the remarkable acceleration of linear growth which occurs at the time of sexual maturation (Fig. 1a) whether that event is early, normal, or delayed (7). In the absence of normal GH and IGF-I secretion, gonadal steroids have limited growth-promoting effects (Fig. 1b). This is suggested by the subnormal increase of the growth rate in hypopituitary boys treated with testosterone before GH therapy was available (8).

Additional evidence of the effects of sex steroids in the absence of GH action is obtained in patients with Laron dwarfism (9) who present with high GH and very low IGF-I and who attain an adult height of 110 to 140 cm. Among eight of these patients followed longitudinally throughout puberty (10), three girls did not show any significant growth spurt. In contrast, in three boys and two girls who grew at a mean rate of 2.9 cm/yr before...
Fig. 1. Schematic representation of height in relation to age in normal subjects (a), in the absence of normal GH or IGF-I secretion (b), and in the absence of gonadal sex steroids (c). Dark portions of the curves indicate the pubertal growth spurt.

puberty, height velocity increased to 6.5 cm/yr during sexual maturation.

These observations (Fig. 1b) suggest that sex steroids, particularly androgens, may have a direct growth effect independent of GH and IGF-I. This hypothesis is supported by recent observations of a stimulatory effect of sex steroids on rabbit growth cartilage in vitro (11). However, the concept of a GH-independent acceleration of growth by sex steroids cannot be established in the clinical situations described above since it is almost impossible to demonstrate the complete absence of any GH IGF-I effect in those patients. Nonetheless, the acceleration of growth, if any, caused by sex steroids in the absence of normal GH IGF-I is minimal when compared to the normal pubertal spurt.

Sex specificity of gonadal steroid effects on growth. The pubertal growth spurt is generally attributed to androgens in boys and estrogens in girls. While, in females, estradiol is clearly the sex steroid associated with pubertal growth, it is possible that, in males, the growth-promoting effects of androgens are partly mediated through their transformation into estrogens. This hypothesis is supported by the following lines of evidence.

In Fig. 2 are illustrated the mean plasma levels of estradiol and testosterone (calculated from Refs. 12–17) in relation to the pubertal growth spurt in both sexes (18). The interpretation of such data on plasma sex steroid levels must be made with caution in the absence of longitudinal observations of integrated night-time and day-time levels in relation to bone age. Also, we do not know the threshold plasma levels of estradiol and testosterone required for growth stimulation. Nonetheless, it is interesting to note (Fig. 2) that a sharp increase in testosterone secretion occurs quite late during puberty. Therefore, at the time of maximal height velocity, plasma testosterone levels in boys and girls are, respectively, 18% and 44% compared to concentrations achieved at 15–16 yr. In contrast, estradiol increases earlier than testosterone in both sexes. At peak height velocity, estradiol levels in boys and girls represent 75% and 72%, respectively, of the concentration achieved at 15–16 yr.

In both sexes, aromatase has been found in several extraglandular locations such as muscle and adipose tissue (19) and it has been shown that only small amounts of estrogens are produced by the testes. Most of the estrogen is formed peripherally in male subjects (20, 21). In addition to bone marrow (22), conversion of androgen precursors into estrogens could occur in the cartilage although we still lack evidence supporting such hypothesis. An indirect argument for the role of estrogens in longitudinal bone growth in the male is the presence of estrogen receptors in osteoblast-like cells (23, 24).

A physiological role for estrogens in the male pubertal growth spurt is also supported by the correlation between integrated GH concentrations and plasma estrogen concentrations (25) while no correlation is seen with testosterone (25–27). In addition, at puberty in both sexes, the rising plasma levels of IGF-I are correlated to total estradiol plasma levels (28) or free estradiol concentrations but not with testosterone (25). However, it is possible that circadian and episodic fluctuations in plasma sex steroid levels have biased those studies.

A more direct demonstration of a role for estrogens in the male pubertal growth spurt has been provided by Caruso-Nicoletti et al. (29). These authors have shown that a 4-day infusion of estradiol to five prepubertal or early pubertal boys resulted in a 2.6- and 2.0-fold increase in ulnar growth velocity when estradiol plasma levels are 10, 16, and 96 pg/ml, respectively (29). Higher concentrations of estradiol than those derived physiologically from testosterone do not induce any significant
growth effect (30). These data indicate that, in male subjects, estrogens may have a biphasic effect similar to that observed in girls.

A convincing demonstration of the role of endogenous or synthetic estrogens in males has been provided by Zachmann et al. in nine patients with the androgen insensitivity syndrome (31). These phenotypic females with an XY karyotype achieve a pubertal growth spurt quantitatively and chronologically similar to normal girls, with plasma estradiol concentrations within or above the normal range for pubertal males. The observation of accelerated growth in prepubertal boys with gynecomastia caused by increased testicular (32) or peripheral (33) aromatase activity also suggests a mediatory role for estrogens in male growth. Finally, a contribution of estrogens to pubertal growth in boys is suggested by the significant reduction of height velocity to 6 cm/yr in three patients with testotoxicosis treated using the aromatase inhibitor testolactone together with the antiandrogen spironolactone while growth rate was 12 cm/yr using spironolactone as a single therapy (58).

While several observations support the role of estradiol in the male pubertal growth spurt, there is no clear evidence of a physiological role for androgens in the female pubertal growth spurt. Recently, Rosenfield (34) showed that long-acting testosterone 28 mg/m²·month given for 6 months to five Turner patients with pubertal bone ages (10.6–12.8 yr) resulted in a 2-fold increase in height velocity. This effect may have involved testosterone conversion into estradiol. However, it is likely that androgens are themselves growth-promoters in girls since treatment of patients with gonadal dysgenesis (35, 36) or hypopituitary girls (37) using nonaromatizable androgenic steroids (oxandrolone and norethandrolone) induces a significant acceleration of the growth rate.

The growth-promoting action of androgens and estrogens is at least partly explained by their stimulatory effect on integrated GH concentrations (8, 26, 38). In contrast, oxandrolone does not affect 24 h GH secretion and plasma IGF-I levels (39). In a more recent study, a significant but modest (+20%) increase in plasma IGF-I levels has been reported after 3 months of oxandrolone therapy in boys with constitutional delay of puberty (40). Such an effect does not occur in prepubertal boys and could be related to the increase in GH secretion or in testosterone production at the beginning of puberty and during its progression (41). However, a physiological role for endogenous androgens in the female pubertal growth
spurt cannot be inferred from the therapeutic effects of oxandrolone.

Interactions of GH with sex steroid secretion. Some authors have examined the question whether or not sex steroid secretion is influenced by possible interaction of GH with the pituitary-gonadal system. In hypopituitary patients, the gonadotropin responses to synthetic GnRH are not different before and during GH therapy (42). This suggests that GH does not interact with FSH and LH secretion at the pituitary level.

The interactions of GH at the gonadal level have been investigated through sex steroid responses to human CG (hCG). Early studies by Rivarola et al. (43) and by Zachmann (44) in 1972 suggested a stimulatory effect of GH on testosterone secretion after prolonged hCG administration in three postpubertal patients. More recently, in prepubertal hypopituitary boys, Zipf et al. (45) and Maes et al. (46) did not observe any significant change in testosterone responsiveness to HCG after, respectively, 4 and 3 months of GH therapy. However, in similar patients, Kulin et al. (47) found the testosterone response to hCG to increase after a longer period of GH therapy ranging from 6 to 12 months. These latter authors were unable to observe any GH-related change in estradiol secretion induced by HCG in somatotropin-deficient girls (48).

The decreased phallic size in some newborns with GH deficiency (49) suggests a peripheral or intratesticular interaction of GH with sex steroid production or action during intrauterine life. There is no clinical data to support a significant interaction at puberty. Also, evidence is lacking of a major role for GH in priming pituitary-gonadal maturation or in maintaining its functional level in adults. However, rapid onset of puberty has been observed within a few months after initiation of hGH therapy in hypopituitary patients (50). We lack detailed studies on pituitary-gonadal functions after withdrawal of GH replacement therapy in patients with isolated GH deficiency.

While the paracrine role of IGF-I in the gonads is well established, its regulation by pituitary GH has not been fully elucidated. Experimental data indicate that the gonadotropins stimulate IGF-I production by cultured porcine granulosa cells (51) and IGF-II gene expression in human granulosa cells (52). In addition, testicular IGF-I receptors may be induced by hCG and, conversely, there is an up-regulation of hCG receptors by IGF-I (53). Recent data suggest that GH may also be involved in the control of ovarian IGF-I secretion (54).

B. GH

Growth effects of GH in the absence of sex steroids. In patients with sex steroid deficiency and normal GH secretion (Fig. 1c), no pubertal growth spurt occurs. Patients with congenital hypogonadism (anorchia or Kallman’s syndrome) have a normal pattern of prepubertal growth (55). However, no obvious pubertal growth spurt occurs in GH-treated boys with gonadotropin deficiency unless sex steroids are administered (56, 57).

A so-called “normal” adult height is attained by hypogonadal patients with isolated gonadotropin deficiency not treated with sex steroids before epiphyseal fusion (58, 59). This indicates that, on the whole, adult stature is not affected by the absence of sex steroids. However, body proportions are not normal in those patients. This is because the adolescent spurt in sitting height is predominantly controlled by sex steroids and relatively independent of GH, while the spurt of legs is GH-dependent (56). Therefore, the apparently normal expression of growth potential in the absence of sex steroids results from an excess in leg growth relative to growth of the trunk.

Interactions of sex steroids with GH secretion. Numerous authors have shown that sex steroids modulate GH secretion. While early studies were focused on GH response to pharmacological tests, more recent observations have examined the amplitude, the frequency, and the integrated concentrations of intermittent GH secretion.

An early study of testosterone effect on GH response to insulin-induced hypoglycemia or arginine in boys with constitutional delay of puberty was reported by Martin et al. in 1968 (60). These authors confirmed their earlier observation by showing that 21 of 22 boys, with constitutional delay of puberty and a subnormal GH responsiveness, normalized their GH levels after a 5-day course of testosterone propionate therapy, 25 mg/day (61). In 4 patients with anorchia, Illig and Prader (62) found an impaired GH response to insulin-induced hypoglycemia which was normalized by a 2- to 3-month testosterone therapy while the same treatment did not affect GH responsiveness in a GH-deficient patient.

In a cohort of 105 patients with constitutional growth delay, Gourmelen et al. (63) reported that 23% had a reduced GH response to ornithine or insulin-induced hypoglycemia. After spontaneous puberty was begun, GH response was normalized, confirming early observations on the increase of GH response to arginine- or insulin-induced hypoglycemia during normal puberty (64, 65). Estrogens are also effective in increasing GH secretion after provocative stimuli as shown by studies on the effects of short-term administration of relatively high estrogen doses (66–71).

The study of integrated GH concentrations has provided information on the physiological interactions between sex steroids and GH. In several studies, integrated concentrations of GH were found to be higher in pubertal
subjects of both sexes than those seen before puberty and during adulthood (25, 38, 72-75). In girls with central precocious puberty, integrated concentrations of GH are increased 1.5 times over pretreatment values (76) and reduced to 0.5 times the pretreatment level after 6 months of treatment with a GnRH agonist (77). In boys with constitutional delay of puberty (39, 78) and in males with hypogonadotropic hypogonadism (79), integrated GH concentrations are increased up to 4.3 times after chronic testosterone therapy.

During spontaneous puberty, the priming effect of sex steroids on integrated GH concentrations is dependent on an increased amplitude of GH secretory episodes while frequency is not affected (25, 80). In addition, testosterone administration to patients with delayed puberty or hypogonadism results in a 2.1- to 3-fold increase of GH pulse amplitude whereas pulse frequency is unchanged (39, 79, 80).

Some observations do not corroborate a stimulatory effect of sex steroids on GH secretion. Spiliotis et al. (81) did not observe any significant change in integrated concentrations of GH between prepuberty and puberty, in accordance with a previous report by Thompson et al. (26) and with some of the observations by Drop et al. (82). These different results may be explained by the heterogeneity of patients studied; that is, the administration of sex steroids or the occurrence of spontaneous puberty will increase GH secretion in patients with constitutional delay of puberty but not in those having any form of GH deficiency.

Contribution of GH to the pubertal growth spurt. In patients with isolated GH deficiency, the pubertal growth spurt is severely reduced, which contributes in part to the shortened adult stature (83, 84). This observation unequivocally establishes GH as a prerequisite to the growth spurt. However, the threshold level of GH secretion required to obtain a pubertal spurt may be low since a moderate but significant acceleration of the growth rate (6.8 cm/yr) is seen in girls with central precocious puberty and deficient GH response (<5 μg/ml) to provocative stimuli (114). Also, it is unclear whether the sex steroid-induced rise in GH secretion is a requirement for achieving the spurt. In fact, a pubertal growth spurt occurs under constant GH replacement in hypopituitary patients (56, 57, 85–90). However, in such individuals, the mean peak height velocity during spontaneous and testosterone-induced puberty is 7.6 and 7.3 cm, respectively, a consistently lower gain than the average peak of 10.3 cm/yr (91, 92) found in normal boys. Noteworthy, the peak height velocity is physiologically lower in late maturers (18) who are close to patients with untreated isolated GH deficiency in terms of timing of onset of puberty. Also, the lower peak height velocity in those

patients may result from the nonphysiological schedule of GH administration which was 3 times a week in the above studies.

An alternative explanation is the absence of a puberty-related increase in GH dosage. This hypothesis is not supported by the data of Job et al. (93) in patients with isolated GH deficiency. These authors obtained mean total pubertal height gains of 21.0 and 14.3 cm in hypo-pituitary boys and girls, respectively, while the normal spurs are 28 and 25 cm. They found no relationship between pubertal height gain and hGH dosage varying between 12 and 26 IU/kg·yr. As pointed out by Job et al., these variations of GH dosage may be too small since there is an exponential relationship between growth rate and hGH dosage (94, 95). Still, a critical factor is the discrepancy between GH administration 3 times a week and physiological GH secretory pulses several times a day since the so-called replacement doses of GH are well above the normal production rate of GH.

C. Somatomedin C/IGF-I

Plasma IGF-I: origin and role in growth. Since Salmon and Daughaday (96) described the growth-promoting action of GH as dependent on an intermediate factor identified later as somatomedin C or IGF-I, evidence has accumulated to establish the GH-dependent production and release of IGF-I as a fundamental mechanism in the endocrine control of growth (97-99). Studies attempting to localize the site of IGF-I production failed to identify a major and exclusive source for the pool of IGF-I circulating in plasma, although it is generally agreed that, in man, at least half the circulating IGF-I comes from the liver. The existence of different IGF-I sources is consistent with the observation of IGF production by several tissues from human fetuses (100, 101) and adult fibroblasts (102, 103), indicating its possible paracrine or autocrine role as well as endocrine function.

In the rat, a direct action of GH on bone growth has been shown by Isaksson et al. (104). This effect appears to involve IGF-I production locally by the growth plate under the control of GH as shown recently in that species (105). To date, it is unclear how and to what extent circulating IGF-I and IGF-I synthesized locally in the cartilage contribute to skeletal growth. Other important methodological and physiological questions arise from the existence of certain IGF-I binding proteins which also make interpretation of IGF-I circulating levels difficult. The unsaturated IGF-I binding protein level (106) and its radioimmunoassayable low molecular weight form (107) are high in conditions associated with low plasma IGF-I levels, such as hypopituitarism, while the binding protein is lowered by a treatment using GH which restores normal IGF-I secretion. This indicates
that IGF-I may regulate negatively the production of some fractions of its binding protein while others are positively regulated.

In hypopituitary or short-stature patients, growth response to GH therapy is not correlated with plasma IGF-I levels (108–110). A similar dissociation between growth rate and plasma IGF-I levels is found in late normal puberty after the growth spurt (28, 111, 112) and during GnRH agonist therapy in central precocious puberty (77, 113), while before therapy, the growth rate and the plasma IGF-I levels are positively correlated (114). These results are consistent with local production of IGF-I in the cartilage. In those cases, plasma levels of IGF-I represent more likely an index of total production, not necessarily a requirement for longitudinal growth.

**Interactions of sex steroids with IGF-I.** At puberty, there is a characteristic rise in plasma concentrations of IGF-I (28, 115–117). Detailed studies of this phenomenon have shown that this increase in IGF-I plasma levels occurs 1 yr earlier in girls than in boys (112) and is correlated to plasma estradiol levels in both sexes (28, 31). In children with central precocious puberty, IGF-I shows a premature rise (76, 77) which can also be induced by treating hypogonadal patients with androgens (39, 79, 118) as well as with estrogens (119–121). Thus, experimental and clinical evidence indicates that increased sex steroid secretion is associated with stimulation of GH and IGF-I and accelerated rates of growth and of bone maturation (Table 1).

The growth-promoting effect of sex steroids, however, does not necessarily require an increase in plasma concentrations of IGF-I. In hypopituitary boys under GH replacement therapy at a constant dosage, testosterone accelerates growth without concomitant stimulation of plasma IGF-I concentrations (111, 118, 122). A similar finding is present in patients with gonadal dysgenesis treated with low-dose estrogens (120, 123, 124). In these conditions and in others such as the late stages of normal puberty and high-dose estrogen treatment in tall girls, variations of plasma IGF-I levels do not parallel the changes in plasma sex steroid concentrations (Table 1). Some of those discrepancies may be explained by a dose-related biphasic effect of estrogens (28, 120).

In African pygmies, an illustration of the role of IGF-I at puberty has been proposed by Merimee et al. (125, 126). They reported that these subjects develop normal sex characteristics and pubertal plasma levels of sex steroids but show no pubertal growth spurt and end up with a mean adult stature of 144.0 cm. The proposed explanation is that plasma levels of IGF-I that are normal before puberty only increase to 35–49% of the concentrations seen during normal puberty. In fact, careful examination of the original growth data (127) indicates that linear growth accelerates at puberty in pygmies; the apparent absence of a pubertal spurt results quite likely from the use of pooled cross-sectional observations (Tanner J., personal communication). Reevaluation of auxological data will be necessary for correlating IGF-I levels and quantitated parameters of pubertal growth.

Are the effects of sex steroids on IGF-I secretion mediated by GH? Such a mechanism is strongly suggested by the absence of changes in IGF-I secretion after sex steroid administration to hypopituitary patients under a constant regimen of GH therapy (111, 118, 122). Also, observations during normal or precocious puberty show a direct relationship between the increase of IGF-I and integrated GH concentrations (25, 76), both changes being reversed during GnRH agonist therapy (77).

Some stimulatory effects of sex steroids on IGF-I may be independent of GH since increased IGF-I levels with unchanged GH secretion have been observed during low-dose estrogen or oxandrolone therapy in gonadal dysgenesis patients (36, 128). The unchanged plasma IGF-I levels reported by others during similar treatments (35, 123, 124) do not exclude a local stimulation of IGF-I by sex steroids in the cartilage. In other conditions, a dissociation between IGF-I and GH secretion is observed. In acromegalic patients or in adolescent girls with tall stature, estrogen therapy at relatively high dosages does not affect IGF-I levels (70) or reduces IGF-I concentrations (66, 68, 69, 129) while GH secretion is elevated in those conditions.

### Table 1. Interactions between sex steroids, IGF-I, and growth in different conditions resulting in increased sex steroid level

<table>
<thead>
<tr>
<th>Condition</th>
<th>GH secretion</th>
<th>IGF-I plasma level</th>
<th>Growth rate</th>
<th>Bone maturation rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal puberty (early stage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central precocious puberty</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex steroid therapy in hypogonadal patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-dose estrogen therapy in gonadal dysgenesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone therapy of GH-treated boys</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal puberty (late stage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrogen therapy of tall girls</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**D. Adrenal sex steroids**

A possible role for adrenal androgens in the control of growth arose from the short adult height observed in
men and women with untreated congenital adrenal hyperplasia. In this condition, high testosterone levels are well established in addition to increased Δ4-androstenedione and dehydroepiandrosterone (DHEA) secretion. From the data of Thamdrup (1), Styne et al. (3), Jones-Klingen Smith et al. (4), Urban et al. (5), and Di Martino-Nardi et al. (6), mean adult height observed in 9 male patients and 39 female patients never treated before adulthood was 153.8 cm and 150.6 cm, respectively. This is an obvious, but not striking, reduction in adult stature, given the prolonged period of androgen excess.

A stimulatory role for adrenal androgens in the control of growth in normal children was suggested by the concomitant onset of adrenarche (12, 13) and an increase in height velocity observed in prepubertal children around 7-9 yr of age (130). In contrast, in hypopituitary boys and girls, or other patients with absent adrenarche, physiological replacement using long-acting injectable DHEA or its short-acting oral form (DHEA-sulfate) for 1 to 2 yr failed to elicit any significant increase in height velocity (131-133). Thus, an excess of adrenal androgens and testosterone has been shown to accelerate linear growth and bone maturation. Although these hormones cause premature growth arrest and short stature in pathological conditions, there is no evidence for a physiological role of adrenal androgens in the control of normal growth.

E. Summary: hormonal constituents of the pubertal growth spurt

In Fig. 3 are represented the three pathways of sex steroid interaction with growth at puberty.

1. Sex steroids may themselves have a growth-promoting action independent of GH and IGF-I, but this seems to be a rather minor contribution to the pubertal growth spurt.

2. The major mechanism is the increased amplitude of GH secretory episodes in the presence of sex steroids, estradiol being the putative mediator of this effect. GH in turn stimulates IGF-I production, accounting for or reflecting the increased growth rate.

3. In the absence of GH increase, another possible mechanism is the direct interaction of sex steroids with IGF-I secretion. As detailed in the following section, this effect is biphasic for estrogens since only low doses are stimulatory while high doses are inhibitory for IGF-I.

1 Editor’s comment: The failure of DHEA administration to increase height velocity does not exclude the possibility that adrenal androstenedione may promote prepubertal bone growth by conversion to estrogen. DHEA is a much less efficient precursor of peripheral estrogen synthesis than is androstenedione (see Ref. 183).
from the growth rate seen immediately after onset of puberty.

B. Final height predictions

Obviously, final height cannot be determined until epiphyseal cartilages have closed. Since it takes such a long time to attain final height, in the clinical setting we attempt to predict the ultimate stature of patients in order to evaluate the likely effects of therapeutic modalities. For instance, in patients with central precocious puberty treated with GnRH agonists, there are no data available on ultimate height so that, to date, only predictions can be used.

Some auxological parameters studied in relation to final height are summarized in Table 2. Adult stature represents the sum of height gains obtained at different periods of life. Puberty is the last important period of life for height gain since postpubertal growth is minimal. At each growth period, including puberty, height gain is the product of two parameters: height velocity and duration of growth. For a given period of growth, height velocity is the height increment (ΔHeight) over Δchronological age. During that period, duration of growth is a direct function of chronological age but inversely related to Δbone age, which is the rate of bone maturation. Thus, height gain during a given period of life is directly related to Δheight and inversely related to Δbone age. Consequently adult stature is also a direct function of Δheight and an inverse function of Δbone age.

According to the statements above, predictive evaluation of the effects of any endocrine condition or therapy

---

**Table 2. Auxological parameters used to evaluate the relative influences of growth rate and age on adult stature**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prenatal length gain</td>
<td>+</td>
</tr>
<tr>
<td>Length gain during infancy</td>
<td>+</td>
</tr>
<tr>
<td>Prepubertal height gain</td>
<td>+</td>
</tr>
<tr>
<td>Pubertal height gain</td>
<td>+</td>
</tr>
</tbody>
</table>

**Calculation summary**

\[
\text{Predicted adult height} = \Delta \text{Height} / \Delta \text{Bone age}
\]

\[
\Delta \text{Height} = \Delta \text{Height} / \Delta \text{Chronological age} \times \Delta \text{Chronological age}
\]
on ultimate height must rely on studies of the rate of linear growth (Δheight) vs. the rate of bone maturation (Δbone age). Before adult stature is attained, the three following parameters are commonly used in order to relate growth rate and bone maturation rate (Table 2): the ratio of Δheight age to Δbone age (ΔHA/ΔBA), the Δpredicted adult height and the ΔStandard Deviation Score (SDS) of height for bone age. These three parameters are all dependent on the estimation of bone age which includes errors inherent to the reading of the x-ray film and the characteristics of the children used as controls. These errors restrict the significance of any method of final height prediction. In addition, the degree of shortness may bias the calculations used to estimate the ratio between Δheight and Δbone age. Such biasing effects can be shown using theoretical growth data (Fig. 5).

In Fig. 5a are illustrated theoretical data of height in relation to bone age in three subjects. These subjects differ only by their height at the beginning of a 1 yr study (140, 155, and 170 cm) while they show the same height gain of 5 cm and the same increase in bone age from 14.0 to 15.0 yr (ΔBA = 1.0 yr) during the study. In Fig. 5b, it is shown how height ages and ΔHA are calculated using the heights of the three subjects and the 50th centile curve of height from the standards of Tanner and Davies (18). Since the 50th centile curve is not rectilinear but changes with age, particularly at puberty, the calculation of height age is markedly influenced by the degree of shortness which is different among the three subjects. This is why they show ΔHA varying between 0.5 and 1.4 yr while their ΔBA is 1.0 yr. Thus, calculation of ΔHA/ΔBA ratio is biased by the degree of short stature which affects ΔHA. Because of such biasing effect, ΔHA/ΔBA does not represent a suitable index for relating growth rate and bone maturation rate.

Calculation of predicted adult height provides another means of integrating the rate of growth and the rate of bone maturation. This calculation can be done using tables or equations based on sex, height, and bone age which are the main data used to predict final height. In a previous study by Zachmann et al. (135) comparing different methods of adult height prediction, it was concluded that the method of Bayley-Pinneau (136) using bone ages rated according to Greulich and Pyle (137) provided the most consistent predictions. Final height predictions are less accurate in patients showing marked deviations from the range of physiological variations in height or marked differences between bone age and chronological age. In addition, height predictions may be biased by the degree of shortness, as shown in Fig. 5c. Using the equations of Tanner et al. (138), we have calculated predicted adult heights in the three subjects studied for 1 yr. While those subjects had identical bone ages, height gains, and ΔBA, they had different changes in predicted adult heights. The tallest one would gain 0.8 cm while the shortest would lose 1.9 cm. This represents a relatively minor error after a 1 yr study. However, the

![Fig. 5](https://academic.oup.com/edrv/article-abstract/9/4/467/2548915/3881807)
biasing effect of the degree of short stature on the calculation of predicted adult height may increase with the length of the study period.

The growth rate can also be related to the rate of bone maturation by calculating the standard deviation score (SDS or Z score) of height for bone age. This is the difference between a patient’s height (x) and mean normal height for the same bone age (\(\bar{x}\)), divided by the SD of height for that bone age. Thus, SDS = \((x - \bar{x})/SD\).

Using this calculation, it is shown in Fig. 5d that the same \(\Delta\)SDS of height for BA \((-0.23\ SD)\) is found in the three subjects studied with different degree of short stature. This indicates that \(\Delta\)SDS of height for BA is not biased by the degree of short stature. However, SDS of height for bone age still involves errors inherent to bone age estimation. In addition, the standard deviations of height for chronological age are used improperly for relating height to bone age since there is no available data base of height for bone age.

Thus, when pubertal growth is studied, the important parameter is total pubertal height gain which is the product of mean height velocity and duration of pubertal growth. When we predict how adult stature can be affected by therapies inducing or delaying puberty, height gain and \(\Delta\)BA during therapy are the two major factors. In order to relate these two factors, methods using height gain and \(\Delta\)BA should not be considered carefully. Further recommendations should rely on retrospective studies of different methods for adult height prediction in specific groups of subjects or patients having attained adult stature. It is likely that the methodological errors would be minimized using specific prediction methods for each type of growth disorder.

IV. Role of Sex Steroid Dosage

Factors such as age at onset of sex steroid action and dosage of sex steroids may determine differences in the rates of growth and bone maturation during pubertal growth. Those two key factors are particularly important in the therapeutic management of patients with disorders of puberty. In the following sections, the role of sex steroid dosage and age at onset of puberty on pubertal growth, bone maturation rate, and final height will be examined in both sexes.

A. Role of estrogens

Effects of estrogen dosage on pubertal growth. In hypopituitary girls, very limited studies have been published on growth during estrogen therapy (87, 139, 140). The major data bearing on the importance of estrogen dosage for growth response have been obtained in patients with gonadal dysgenesis (vide infra).

In 1974, Rosenfield and Fang (119) reported on the growth response to low-dose estrogen in subjects with gonadal dysgenesis. In contrast, high doses (equivalent to more than 1 \(\mu\)g/kg-day of ethinyl-estradiol), had been shown not to affect the growth rate (141). In a short-term study using different estrogen doses, Ross et al. (120) observed a 2-fold increase in the growth rate of the ulna by ethinyl-estradiol 0.1 \(\mu\)g/kg-day. Higher dosages of 0.4 and 0.8 \(\mu\)g/kg-day were not effective on bone length, indicating the biphasic nature of estrogen effects upon growth. Although this study only considered the growth of the limbs, growth of the trunk is equally important to the pubertal spurt. More recently, in a double-blind, placebo-controlled study using 0.1 \(\mu\)g/kg-day ethinyl-estradiol for 6 months, the same group has shown a 70%-increase in height velocity induced by estrogens (123).

In Fig. 6, the results from 8 available studies on estrogen effects in patients with gonadal dysgenesis are compiled (119, 121, 123, 124, 142–145). The data are plotted in relation to bone age at onset of estrogen therapy, which is variable over a range of 6 yr between 8.1 yr (145) and 13.8 yr (143). In all these studies, bone ages were rated according to the method of Greulich and Pyle (137) except for patients starting treatment at 13.0 yr of bone age in whom calculations were made according to the method of Tanner et al. (138). In order to include the patients studied by Ross et al. (123), mean bone age was arbitrarily considered to be delayed 1.5 yr below their mean chronological age, based on the findings of Martinez et al. (124). While weight was not stated by the authors, body weight-related doses of estrogen were calculated for a 40-kg patient (119, 141–143, 145). The following drug equivalents were used in this compilation: 10 \(\mu\)g/day ethinyl-estradiol (EE) = 1 mg/day 17\(\beta\)-estradiol (given orally) = 2 mg/month of long-acting estradiol ester (given im) = 0.3 mg/day conjugated estrogens (given orally).

The interpretation of the effects of estrogen dosage upon growth in patients with gonadal dysgenesis is difficult since available information involves differences in estrogen dose and differences in age at onset of administration. When these studies are reviewed (Fig. 6), the dose of estrogen used does not seem to play a major role in determining the immediate growth response. This is quite clear in the 4 groups of patients beginning treatment between 11.1 and 12.1 yr of bone age (121, 142, 143, 145). They exhibit similar growth rates despite the use of very different estrogen dosages. However, it is still possible that estrogen dosage will influence the total pubertal height gain since the growth rates observed during the first year of estrogen therapy may not parallel the total pubertal height gain.
GROWTH IMPACT OF PUBERTY

Effects of estrogen dosage on the rate of bone maturation.

In patients with gonadal dysgenesis and, by inference, in normal girls, the dose of estrogen may be critical for the rate of bone maturation. In several studies of Turner's patients compiled in Fig. 7, left panel (119, 123, 124, 142, 145), ΔBA/ΔCA has been estimated according to Greulich and Pyle (137). In order to include the data from Ross et al. (123) in this compilation, bone age at onset of estrogen therapy was assumed to be 8.5 yr (1.5 yr below mean chronological age). As shown in Fig. 7, in patients who began estrogen therapy before a mean bone age of 10 yr, Kastrup et al. (145) observed a mean ΔBA/ΔCA of 2.92 using a daily dose of ethinyl estradiol ranging between 0.1 and 0.4 µg/kg. In contrast, using a lower dose of 0.1 µg/kg, Ross et al. (123) and Martinez et al. (124) found ΔBA/ΔCA to be 0.92 and 1.65, respectively.

Effects of estrogen dosage on final height. To date, we lack information about final height in relation to the dosage of estrogens used as replacement therapy. In tall girls, treatment with high doses of estrogens has been shown to induce an acceleration in bone maturation accounting for the decrease in ultimate height (66, 129, 146–148). This indicates that the biphasic effect of estrogens on the growth rate differs from the consistent acceleration in bone maturation rate seen with the administration of high doses (≥0.1 mg/day) of ethinyl estradiol (149).

B. Role of androgens

Effects of androgen dosage on pubertal growth.

In hypopituitary boys, pubertal growth has been studied during therapy with testosterone enanthate at different dosages ranging between 100 and 250 mg/month (57, 85–87, 89, 90). In these studies (Fig. 8), treatment was started at similar bone ages (12.8–14.0 yr). In addition, hGH therapy was given at similar doses varying between 12 and 19.5 IU/week. While the different dosages of testosterone resulted in minimal differences in peak height velocity, between 6.3 and 8.0 cm/yr, the total pubertal height gain was 2-fold higher using testosterone 100 mg/month compared to using 250 mg/month (Fig. 8). This illustrates not only the importance of testosterone dosage but also the discrepancy between peak height velocity and total pubertal height gain which has been described above.

A monthly injection of 100 mg testosterone enanthate, is, in fact, too high for beginning hormone replacement therapy (86). As shown in Fig. 9, GH-treated hypopituitary patients who were given testosterone enanthate 100 mg/month revealed an earlier occurrence of stages 4 and 5 of genital development and an earlier achievement of peak height velocity than hypopituitary boys developing spontaneous puberty. This is consistent with plasma testosterone levels which were higher during therapy than during the first year of spontaneous puberty. It is to be noted that the testosterone levels measured the first week after the injection would have been even higher.

Effects of androgen dosage on the rate of bone maturation.

During normal puberty, sex steroids may accelerate the bone maturation rate. In boys Buckler (150) reported an acceleration of bone maturation rate (ΔBA/ΔCA = 1.73) concomitant with the peak height velocity. In hypopituitary boys, dosage is also important for the effect of testosterone on bone maturation. As shown in Fig. 8 (lower panel), ΔBA/ΔCA is less in patients treated with testosterone enanthate 100 or 150 mg/month (57, 86) than in those receiving 200 or 250 mg/month (89, 90).
Effects of androgen dosage on final height. In excessively tall boys, long acting esters of testosterone given at a high dosage of 500 mg twice a month result in a reduction of final height vs. adult height predicted before therapy (151).

In hypopituitary boys who have been treated with replacement doses of long acting testosterone usually varying between 100 and 250 mg/month, it is difficult to draw conclusions since several other important factors such as age at onset of GH therapy and height at onset of puberty may interact. In addition, the amount of testosterone given to initiate therapy and the duration of low dose treatment may play some role. Nonetheless, data on adult stature obtained in different studies (85–87, 89, 90) are in a relatively narrow range between —1.4 and —2.0 SD, suggesting that, in the range of doses used (100–250 mg/month), there is no major effect of androgen dosage on final height. Lower doses (25 or 50 mg/month) maintained for the first year of treatment require further study.

V. Role of Age at Onset of Puberty

Bone age represents an index of maturation which is more closely related to growth than chronological age. This is particularly obvious for patients who deviate significantly from the normal tempo of growth and puberty. In some instances, data on bone age may not be available. Therefore, puberty and final height have also been studied in relation to chronological age in male subjects.

A. Girls

Effects of age at onset of female puberty on pubertal growth. In hypopituitary girls, there is a possible role for bone age in determining growth response to sex steroids. In GH-treated girls starting estrogen therapy at mean bone ages of 12.3 (139) and 13.2 yr (87), total pubertal height gain is minimal (2 and 5.2 cm, respectively). Such a low response of growth to estrogens has been confirmed by Rolland et al. (140). In contrast, during spontaneous puberty in GH-treated girls, total pubertal height gains of 22 (87) and 23 cm (85) have been reported. These differences in pubertal growth may relate to the bone age at onset of spontaneous breast development (10.1 and 10.4 yr, respectively) compared to the age at onset of estrogen therapy (12.3–13.2 yr).

Interesting information on the role of age on growth response to estrogens has also been obtained in patients with variants of gonadal dysgenesis. These individuals do not represent the most appropriate model for sex steroid effects on growth since there is impaired growth during intrauterine life and during the prepubertal period as well (152, 153). In addition, relatively high dosages of GH are required to improve growth in Turner patients (35, 154).

As shown in the upper panel of Fig. 6, in accordance
with observations in untreated patients (152, 153), there is a progressive decline of pretreatment height velocity with age. Growth response during the first year of estrogen therapy (Fig. 6, middle panel) follows a similar age-related reduction from 7.5 to 1.7 cm/yr. These findings not only reflect the impact of pretreatment height velocity but also a decrease in responsiveness to estrogens with age. In fact, the increase in height velocity over pretreatment level was 60-113% before 10 yr of bone age, 40-89% between 11 and 12 yr, and 21-46% between 13 and 14 yr.

**Effects of age at onset of female puberty on the rate of bone maturation during puberty.** As shown in Fig. 7 (left panel), during estrogen administration to patients with gonadal dysgenesis, ΔBA/ΔCA tends to decrease in relation to bone age at onset of therapy. Such a negative relationship between ΔBA/ΔCA calculated according to Tanner et al. (138) and pretreatment bone age exists in patients with central precocious puberty (155) during treatment with buserelin, a superagonist of GnRH (Fig. 7, right panel). For patients with precocious puberty, a similar correlation has been found by Boepple et al. (156) in girls treated with the [d-Trp⁶-Pro⁹-iV-ethylamide]-GnRH analog.

**Effects of age at onset of female puberty on final height.** While the reduction of adult stature in girls with early exposure to estrogens is well established (1, 2), the effects of late onset of estrogen therapy on final height are unknown. This is partly explained by the low incidence of conditions such as hypogonadotropic hypogonadism or panhypopituitarism in females as compared to males. This question deserves further study, particularly because the growth response to estrogens in girls seems to be more age-dependent than the response to androgens in boys (vide infra).

**B. Boys**

**Effects of age at onset of male puberty on pubertal growth.** In normal children, there is an age-related decrease of
pubertal height gain as indicated by the early observations of Boas (157). Several authors have confirmed this relationship using peak height velocity (91, 92) or pubertal height gain (158) as the index of pubertal growth. In hypopituitary boys, the role of bone age on growth response to testosterone therapy has been known from early data obtained using high doses of androgens (testosterone enanthate ≥ 300 mg/m²·month) before hGH treatment was available. After initiating testosterone administration at a mean bone age of 13.5 yr, Aynsley-Green et al. (57) obtained a maximal growth rate of 5.5 cm/yr during a 1.9 yr period of treatment. This observation is similar to the 5.2 cm/yr reported by Zachmann and Prader (159) under the same conditions. In contrast, when testosterone was started at 8.5 yr of mean bone age, Blizzard et al. (8) obtained a more pronounced increase in height velocity, up to 8.5 cm/yr (recalculated from their data).

As shown in Fig. 10, the parameters of pubertal growth exhibit a similar pattern of variation in relation to bone age in hypopituitary boys and in relation to chronological age in groups of subjects or patients beginning puberty at different ages between infancy and early 20s (134). The total pubertal height gain is negatively related to age at onset of puberty. It can be seen in Fig. 10 that the age-related decrease in total pubertal height gain is explained by a reduction in duration of pubertal growth. In contrast, there are only minor differences in mean pubertal growth rate which has been calculated as the total height gain divided by the duration of puberty.

**Effects of age at onset of male puberty on the rate of bone maturation during puberty.** During testosterone therapy in GH-treated hypopituitary boys (Fig. 7, middle panel), as well as during spontaneous puberty in boys with isolated GH deficiency (86), the rate of skeletal maturation decreases with age at onset of puberty. As a matter of fact, when referred to an average normal ΔBA/ΔCA of 1, patients starting puberty at an early bone age have a rapid rate of bone maturation during puberty while those entering puberty at a late bone age have a slow rate of bone maturation during puberty. The question arises whether or not those age-related differences in bone maturation rate play some role in the different

![Fig. 10. Total pubertal height gain, duration of pubertal growth, and mean pubertal growth rate in relation to age at onset of puberty. Left panels, Individual data of hypopituitary boys (△, spontaneous puberty, ●, testosterone-induced puberty) in relation to bone age. Right panels, data compiled from the literature and studied in relation to chronological age; groups B and C: boys with idiopathic precocious puberty (1, 2); groups D, E and F: normal boys maturing at early, average, and late tempos (18); groups G and H: GH-treated hypopituitary boys with spontaneous and testosterone-induced puberty (86). [Reproduced with permission from J. P. Bourguignon: Acta Paediatr Scand [Suppl] 343, 1988 (134).]
patterns of pubertal growth determined by age at onset of puberty. These different patterns relate to duration of pubertal growth which decreases with age at onset of puberty (Fig. 10). An increased rate of bone maturation would account for a reduced duration of pubertal growth and vice versa. In fact, the opposite phenomenon is observed, a reduced rate of bone maturation being seen in patients with reduced duration of puberty. This indicates that variations in the rate of bone maturation with age at onset of puberty do not contribute to the differences in duration of pubertal growth. Rather, variations in the rate of bone maturation appear as a compensatory mechanism which may counteract, to some extent, the differences in duration of puberty determined by the timing of its onset.

Effects of age at onset of male puberty on final height. As shown in Fig. 11, in boys with idiopathic precocious puberty beginning at a mean age of less than 2.0 yr (n = 5, group B) and 3.9 yr (n = 4, group C), there is a 30.1- and 20.6-cm reduction of final height (1, 2) when compared to 176.8 cm which is the 50th centile of height for normal adult males (18). The observations in central precocious puberty are consistent with the mean adult height reduction of 23.0 cm seen in nine boys with untreated congenital adrenal hyperplasia (1, 3, 5, 6, group A). Also, in girls with central precocious puberty, a direct relationship exists between adult height and age at onset of puberty (2). In boys with severe sexual precocity, the reduction in prepubertal height gain, as indicated by height at onset of puberty (Fig. 11), is much more important than the increase in pubertal height gain and accounts for their reduced adult stature (134).

While severe sexual precocity results in impairment of adult stature (1, 2), similar adult heights are found in longitudinal studies (18) of normal boys maturing at early, normal, or late tempos (Fig. 11: groups D, E, and F). This is in accordance with several reports on normal adult stature in boys with constitutional delay of puberty, not treated with androgens. The differences in adult

**FIG. 11.** Final height, height at onset of puberty, and total pubertal height gain in relation to age at onset of puberty. Left panels, Individual data of hypopituitary boys (A, spontaneous puberty; ○, testosterone-induced puberty) in relation to bone age [Adapted with permission from J. P. Bourguignon et al.: J Clin Endocrinol Metab 63:376, 1986 (86).] Right panels, Data compiled from the literature and studied in relation to chronological age; group A: boys with untreated congenital adrenal hyperplasia (1, 3, 5, 6); groups B and C: boys with idiopathic precocious puberty (1, 2); groups D, E, and F: normal boys maturing at early, average and late tempos (18); groups G and H: GH-treated hypopituitary boys with spontaneous and testosterone-induced puberty (86); group J: men with hypogonadotrophic hypogonadism (58, 59). [Reproduced with permission from J. P. Bourguignon: Acta Paediatr Scand [Suppl] 343, 1988 (134).]
height reported by some authors (160, 161) may be explained by differences in parent’s height (162, 163).

In GH-deficient patients with idiopathic hypopituitarism, late onset of replacement hGH therapy accounts for the possible loss of some growth potential as indicated by short adult stature. However, GH-deficient patients with spontaneous puberty (Fig. 11: group G) can be compared with those treated using testosterone (group H). As shown in Fig. 11, while there is a difference of 3.5 yr of chronological age at onset of puberty between these two groups of patients, the difference in mean final height between both groups is only 4.0 cm (86). Analysis of individual data obtained in hypopituitary boys in relation to bone age (Fig. 11, left panels) indicates the existence of opposite variations in prepubertal and pubertal height gains. Since these variations are of similar importance, they counterbalance one another, resulting in the absence of obvious differences in final height (86). Our observations are consistent with those of Burns et al. (85) and Ranke and Butenandt (87), who found mean adult height to be, respectively, 2.0 and 2.6 cm greater in testosterone-treated patients than in those undergoing spontaneous puberty.

The purest model of severely delayed puberty is provided by patients with isolated gonadotropin deficiency not treated before fusion of growth cartilages (group J, Fig. 11). Recently, Van Dop et al. (59) reported that height attained by these patients was at, or very close to, the 50th centile of height for adult males (59). In another study, mean final height of Kallmann’s patients (58), not treated before age 20, was only 4.2 cm above the 50th centile.

C. Summary: importance of sex steroid dosage and age at onset of puberty for subsequent growth and final height

In Table 3 are summarized the observations discussed in sections IV and V. Sex steroid dosage has some, but not a major effect, on the immediate growth rate. However, the dosage affects directly the rate of bone maturation and may, therefore, reduce the total pubertal height gain. The impact of sex steroid dosage on duration of puberty and adult stature is unknown.

In both sexes, sexual precocity increases the immediate growth rate and the total pubertal height gain, as compared to average maturers. There is an increased duration of puberty which is compensated for by an increased rate of bone maturation. The increase in total pubertal height gain is not sufficient to counterbalance the markedly reduced period of prepubertal growth. Thus, final height is reduced.

In both sexes, delayed puberty reduces the immediate growth rate and the total pubertal height gain, as compared to average maturers. Also, there is, in boys at least, a reduced duration of puberty which is compensated for by a reduced rate of bone maturation. The reduction in total pubertal height gain counterbalances the increase in prepubertal height gain. Thus, final height is not affected.

These conclusions are drawn on the basis of preliminary observations in pathological conditions and the data presented warrant further studies. However, some evaluation of our therapeutic attitudes can be based on the data reviewed above.

VI. Therapeutic Implications

In accordance with Prader (164, 165), we may conclude that sex steroids exhibit remarkable interactions with the dynamics of growth and less striking effects on final height. This observation has several clinical implications for the management of patients with short stature and disorders of puberty.

A. In patients with primary or secondary hypogonadism there is no reason for delaying the onset of sex steroid therapy or any treatment modality for inducing sexual maturation. Available information does not indicate significant growth benefit from a late onset of puberty. The psychological correlates of delayed puberty (166) encourage the practitioner to begin those treatments at an age appropriate for the social or school context. In panhypopituitary patients, a delayed onset of

<table>
<thead>
<tr>
<th>Table 3. Effects of sex steroid dosage and age at onset of puberty on subsequent growth, bone maturation, and final height</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate growth rate</td>
</tr>
<tr>
<td>Estrogen dosage (9)</td>
</tr>
<tr>
<td>Androgen dosage (d)</td>
</tr>
<tr>
<td>Female sexual precocity</td>
</tr>
<tr>
<td>Male sexual precocity</td>
</tr>
<tr>
<td>Delayed female puberty</td>
</tr>
<tr>
<td>Delayed male puberty</td>
</tr>
</tbody>
</table>
pubertal induction will prolong the total period of GH therapy without notable differences in final height.

While evidence accumulates against the statural advantage of a late onset of puberty, some observations emphasize the need to consider the possible benefits of a relatively early onset of sex steroid treatment. In patients with gonadal dysgenesis, the growth response to sex steroid therapy is greater before 10 yr of bone age; in hypopituitary girls, estrogen therapy starting at 10–11 yr of bone age may be required in order to obtain a full pubertal growth spurt. However, the early induction of sex steroid therapy warrants further studies, particularly regarding dosage, before recommendations for such an approach become acceptable and widespread. Prospective research protocols employing only minute amounts of sex steroids might be considered in the first decade of life.

B. There is a current trend to use lower replacement doses of sex steroids than in the past to induce optimal pubertal growth and development. In boys, a monthly dosage of 25–50 mg testosterone enanthate should be used for the first year of therapy. In girls, a daily dose of 0.1 μg/kg ethinyl-estradiol or less may be appropriate. Optimal steroid amounts still need to be determined. Alternatively, chronic, intermittent administration of GnRH may induce a physiological increase in endogenous secretion of sex steroids (167). However, such treatment clearly has practical limitations.

C. Since precocious puberty results in reduced adult stature, it is conceivable that the final growth status of those patients might be improved by maximally delaying sexual maturation using superagonists of GnRH (168–175). However, advancement in bone age results in a reduction of the pubertal height gain and duration of GnRH agonist therapy results in a progressive decline of height velocity below the normal prepubertal limits. Therefore, in order to maximize residual growth, the withdrawal of GnRH agonist therapy should not be too late. The markedly reduced rate of bone maturation seen at late bone ages may be favorable to final height as long as a satisfactory linear growth velocity is maintained during agonist therapy. These various aspects of treatment will not be clarified until adult stature of patients with precocious puberty can be related to growth parameters at the beginning and at the end of treatment.

Although very early onset of puberty reduces adult stature, very late onset of puberty does not increase adult height. Therefore, there is no rationale for delaying the onset of spontaneous puberty beyond the normal bone ages in patients with very short stature. In very short pubertal patients with isolated GH deficiency, two preliminary studies (176, 177) indicate some improvement of predicted adult height with GnRH agonist therapy. However, long term studies are required before such treatment on a widespread basis can be considered.

D. Adult stature is less influenced by pubertal growth than by the height at onset of puberty (92). This finding indicates that prepubertal growth which is predominantly controlled by GH, is critical for adult height. Therefore, early onset of GH therapy and adjustment of GH dosage to obtain a satisfactory prepubertal height velocity may be particularly important for adult height. While interesting data are expected from the widespread use of biosynthetic GH in short children (110, 178–182), such intervention warrants further research to determine the appropriate criteria for treatment and to evaluate long-term effects.

Finally, the behavioral aspects of growth manipulation remain uncharted. The premise of “bigger is better,” requires careful scrutiny. The psychological impact of improving stature must be balanced against other effects that therapy and associated laboratory studies may have on a developing mind. The excitement we bring to our patients as clinical endocrinologists must be tempered by the prudence we bring as thoughtful physicians.

Acknowledgments

I am indebted to my colleagues from the Belgian Study Group for Pediatric Endocrinology for providing contributions of their clinical material. I am particularly grateful to C. Ernould (University of Liège, Liège, Belgium), P. Malvaux and M. Maes (University of Louvain, Brussels, Belgium), M. Vanderschueren-Lodeweyckx (University of Leuven, Leuven, Belgium), and M. Vandeweghe (University of Gent, Gent, Belgium) for helpful discussions. I wish to thank H. E. Kulin from the Endocrine Division, The Milton S. Hershey Medical Center of the Pennsylvania State University, College of Medicine (Hershey, PA), J. M. Tanner, from the Institute of Child Health, University of London (London, England), and G. Van Vliet, from the Department of Pediatrics, University of Brussels (Brussels, Belgium), for taking the time to review very pertinently the manuscript. I acknowledge Mrs. B. Bonhomme and Mrs. M. Beyer for their excellent secretarial assistance.

References

7. Wilkins L 1965 The Diagnosis and Treatment of Endocrine Diseases in Childhood and Adolescence, ed 3. Charles C Thomas Publisher, Springfield, IL
11. Sizonenko PC, Pauner L 1975 Hormonal changes in puberty. III. Correlation of plasma dehydroepiandrosterone, testosterone, FSH and LH with stages of puberty and bone age in normal boys and girls and in patients with Addison’s disease or hypogonadism or premature or late adrenarche. J Clin Endocrinol Metab 41:894
dotrophin in boys with hypopituitarism. Clin Endocrinol (Oxf) 15:463
61. Müller MM, Pham-Huu-Trung MT, Girard F 1979 Transient estrogen rapidly and directly stimulates growth hormone production. J Clin Endocrinol Metab 56:1513
65. Liu L, Merriam GR, Sherins RJ 1987 Chronic sex steroid exposure increases mean plasma growth hormone concentration and pulse amplitude in men with hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 64:651
76. Burns EC, Tanner JM, Preece MA, Cameron N 1981 Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone. Eur J Pediatr 137:155
100. D’Ercole AJ, Stiles AD, Underwood LE 1984 Tissue concentration of somatomedin-C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81:935
113. Mansfield MJ, Rudlin CR, Crigger JF, Karol KA, Crawford JD, Boepple PA, Crowley WF 1988 Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab 66:3
131. Forest MG, De Peretti E, David M, Sempe M 1982 L’adrenarche
GROWTH IMPACT OF PUBERTY


163. Zachmann M, Studer S, Prader A 1987 Short-term testosterone treatment at bone age of 12 to 13 years does not reduce adult height in boys with constitutional delay of growth and adolescence. Helv Paediatr Acta 42:21


